Company intelligence / Profile preview

Charles Gellman

Ownership: Private
Employees: ~20
Development stage: Commercial

Overview

HiDO Health develops an AI-powered robotic device and digital health platform designed to automate at-home medication dispensing and improve adherence. The system uses artificial intelligence, robotics, RFID technology, and video validation to ensure patients take the right medications at the right time without direct caregiver intervention. It aims to reduce preventable hospitalizations/deaths due to non-adherence—an issue responsible for over $300 billion in annual U.S. healthcare costs—and supports both patients with chronic diseases and their caregivers by shifting more care into the home environment.[1][2][4]

Therapeutic areas: Other
Modalities: DeviceDigital health platformArtificial intelligence (AI)RoboticsRemote patient monitoring technology
Industry: Digital Health Medical Devices

Partnerships

None publicly disclosed.

Beyond the preview

Go deeper on Charles Gellman.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Charles Gellman.

Explore the full profile